FY25 consensus $5B. Cuts FY25 adjusted EBITDA view to $850M-$900M from $900M-$950M. Bausch + Lomb (BLCO) provided updated guidance for the full year of 2025 to reflect the estimated one-time impact of the enVista recall and foreign exchange.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Cautious Outlook on Bausch + Lomb Amid enVista Relaunch and Tariff Challenges
- Bausch + Lomb Resumes enVista Lens Production After Safety Recall
- Bausch + Lomb price target lowered to $17 from $18 at RBC Capital
- Bausch + Lomb price target lowered to $15 from $17 at Stifel
- Bausch + Lomb Faces Growth Challenges Amid enVista Lens Recall and Increased Competition